IN2015DN00143A - - Google Patents

Info

Publication number: IN2015DN00143A
Authority: IN; India
Prior art keywords: antibodies; family member; disclosed; cell death; positive cells
Prior art date: 2012-07-09

Application number

Other languages

English (en)

Inventor

DESROCHES Claudine Brigitte Fernande VERMOT

Olivier Frédéric Subiger

Laurence Françoise Jeanne Marie BOURDIN

Original Assignee

Internat Drug Dev Biotech

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-07-09

Filing date

2013-07-09

Publication date

2015-06-12

2013-07-09 Application filed by Internat Drug Dev Biotech filed Critical Internat Drug Dev Biotech

2015-06-12 Publication of IN2015DN00143A publication Critical patent/IN2015DN00143A/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Communicable Diseases (AREA)
Rheumatology (AREA)
Oncology (AREA)
Virology (AREA)
Pain & Pain Management (AREA)
Transplantation (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

IN143DEN2015 2012-07-09 2013-07-09 IN2015DN00143A (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP12305821.6A EP2684896A1 (fr)	2012-07-09	2012-07-09	Anticorps de la famille anti-DR5 ou bispécifique anticorps de la famille anti-DR5 multivalents et leurs procédés d'utilisation
US201261669866P	2012-07-10	2012-07-10
PCT/EP2013/064466 WO2014009358A1 (fr)	2012-07-09	2013-07-09	Anticorps de la famille des anti-dr5, anticorps bispécifiques ou multivalents de la famille des anti-dr5 et leurs procédés d'utilisation

Publications (1)

Publication Number	Publication Date
IN2015DN00143A true IN2015DN00143A (fr)	2015-06-12

Family

ID=46514282

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IN143DEN2015 IN2015DN00143A (fr)	2012-07-09	2013-07-09

Country Status (15)

Country	Link
US (4)	US9611327B2 (fr)
EP (3)	EP2684896A1 (fr)
JP (1)	JP6457386B2 (fr)
CN (1)	CN104619725B (fr)
BR (1)	BR112015000449B1 (fr)
CA (1)	CA2878790C (fr)
DK (1)	DK2877491T3 (fr)
ES (1)	ES2727486T3 (fr)
IL (2)	IL236651B (fr)
IN (1)	IN2015DN00143A (fr)
PL (1)	PL2877491T3 (fr)
PT (1)	PT2877491T (fr)
SG (2)	SG11201500177PA (fr)
SI (1)	SI2877491T1 (fr)
WO (1)	WO2014009358A1 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP3750918A1 (fr)	2015-01-20	2020-12-16	IGM Biosciences, Inc.	Molécules de liaison du récepteur de la superfamille du facteur de nécrose tumorale (tnf) et leurs utilisations
EP3048116A1 (fr)	2015-01-23	2016-07-27	International-Drug-Development-Biotech	Anticorps anti-dr5 avec activité d'apoptose accrue
AU2015380455A1 (en) *	2015-01-26	2017-08-03	Macrogenics, Inc.	Multivalent molecules comprising DR5-binding domains
EP3112381A1 (fr) *	2015-07-01	2017-01-04	FONDAZIONE IRCCS Istituto Nazionale dei Tumori	Anticorps bispécifiques destinés à être utilisés dans l'immunothérapie du cancer
EP3322734B1 (fr)	2015-07-16	2020-09-09	Inhibrx, Inc.	Protéines de fusion se liant à dr5 multivalentes et multispécifiques
WO2017093448A1 (fr) *	2015-12-01	2017-06-08	Genmab B.V.	Anticorps anti-dr5 et procédés d'utilisation de ceux-ci
CN106397594B (zh) *	2016-10-25	2019-06-04	中国药科大学	一种全人源的抗人死亡受体5的激动剂单链抗体及应用
WO2018083126A1 (fr)	2016-11-01	2018-05-11	Genmab B.V.	Variants polypeptidiques et ses utilisations
EP3360898A1 (fr)	2017-02-14	2018-08-15	Boehringer Ingelheim International GmbH	Molécules bispécifiques présentant une immunoréactivité par rapport à tnf-related apoptosis-inducing ligand receptor 2 et à cadherin 17 pour le traitement du cancer
KR20190115057A (ko)	2017-02-10	2019-10-10	젠맵 비. 브이	폴리펩티드 변이체 및 그의 용도
KR101926834B1 (ko)	2017-03-21	2018-12-07	동아에스티 주식회사	항-dr5 항체 및 그의 용도
MX2019014407A (es)	2017-06-07	2020-02-05	Genmab Bv	Anticuerpos terapeuticos basados en hexameros de inmunoglobulina g (igg) mutados.
JP2021510740A (ja)	2018-01-24	2021-04-30	ゲンマブビー．ブイ．	ポリペプチド変種およびそれらの用途
US20200392239A1 (en) *	2018-02-26	2020-12-17	Igm Biosciences, Inc.	Use of a multimeric anti-dr5 binding molecule in combination with a chemotherapeutic agent for treating cancer
EP3788074A1 (fr)	2018-05-03	2021-03-10	Genmab B.V.	Combinaisons de variants d'anticorps et utilisations associées
AU2019412754B2 (en) *	2018-12-26	2026-02-19	Centre National De La Recherche Scientifique-Cnrs-	BTN3A binding proteins and uses thereof
US20220315661A1 (en)	2019-05-09	2022-10-06	Genmab B.V.	Dosage regimens for a combination of anti-dr5 antibodies for use in treating cancer
US20220411529A1 (en)	2019-11-06	2022-12-29	Genmab B.V.	Antibody variant combinations and uses thereof
WO2022018294A1 (fr)	2020-07-23	2022-01-27	Genmab B.V.	Combinaison d'anticorps anti-dr5 et d'un médicament à base d'imide immunomodulateur à utiliser dans le traitement du myélome multiple
KR20240170601A (ko) *	2022-03-02	2024-12-03	월든 바이오사이언시즈, 인크.	신규한 가용성 유로키나제 플라스미노겐 활성화제 수용체(supar) 결합 분자 및 이의 용도

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4342566A (en)	1980-02-22	1982-08-03	Scripps Clinic & Research Foundation	Solid phase anti-C3 assay for detection of immune complexes
US4554101A (en)	1981-01-09	1985-11-19	New York Blood Center, Inc.	Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US5204244A (en)	1987-10-27	1993-04-20	Oncogen	Production of chimeric antibodies by homologous recombination
US5202238A (en)	1987-10-27	1993-04-13	Oncogen	Production of chimeric antibodies by homologous recombination
US5731168A (en)	1995-03-01	1998-03-24	Genentech, Inc.	Method for making heteromultimeric polypeptides
US6284236B1 (en)	1995-06-29	2001-09-04	Immunex Corporation	Cytokine that induces apoptosis
EP0904366A1 (fr)	1996-04-01	1999-03-31	Genentech, Inc.	Polypeptides de l'apoptose apo-2l1 et apo-3
WO1998032856A1 (fr)	1997-01-28	1998-07-30	Human Genome Sciences, Inc.	Recepteur 4 (dr4-recepteur 4 de mort cellulaire) contenant des domaines de mort cellulaire, membre de la superfamille du recepteur du facteur de necrose tumorale (tnf) et se liant a la queue (apo2-l)
US20050233958A1 (en)	1997-03-17	2005-10-20	Human Genome Sciences, Inc.	Death domain containing receptor 5
US6872568B1 (en)	1997-03-17	2005-03-29	Human Genome Sciences, Inc.	Death domain containing receptor 5 antibodies
ATE411385T1 (de)	1998-01-15	2008-10-15	Genentech Inc	Apo-2 ligand
DK1049787T3 (da)	1998-01-23	2005-04-04	Vlaams Interuniv Inst Biotech	Antistofderivater med flere anvendelsesmuligheder
DE69937291T2 (de)	1998-04-02	2008-07-10	Genentech, Inc., South San Francisco	Antikörpervarianten und fragmente davon
PT1192185E (pt)	1999-06-09	2006-11-30	Genentech Inc	Sinergismo de agonista do receptor de apo-2l e cpt-11
US6444640B1 (en)	1999-09-30	2002-09-03	Ludwig Institute For Cancer Research	Compositions of trail and DNA damaging drugs and uses thereof
US7279160B2 (en)	2000-05-02	2007-10-09	The Uab Research Foundation	Combinations of DR5 antibodies and other therapeutic agents
GB0020442D0 (en)	2000-08-18	2000-10-04	Nokia Networks Oy	Data transmission protocol
US20020155109A1 (en)	2001-04-20	2002-10-24	Lynch David H.	Bispecific antibodies that bind TRAIL-R1 and TRAIL-R2
JP4309758B2 (ja)	2001-05-25	2009-08-05	ヒューマンジノームサイエンシーズ，インコーポレイテッド	Ｔｒａｉｌレセプターに免疫特異的に結合する抗体
CA2451680C (fr)	2001-07-03	2011-04-19	Genentech, Inc.	Anticorps humains du dr4 et utilisations
KR20070010046A (ko)	2004-04-06	2007-01-19	제넨테크, 인크.	Ｄｒ5 항체 및 그의 용도
US7632497B2 (en)	2004-11-10	2009-12-15	Macrogenics, Inc.	Engineering Fc Antibody regions to confer effector function
CA2599265A1 (fr)	2005-02-28	2006-09-08	Centocor, Inc.	Compositions de liaison proteinique de forme heterodimerique
JP2009529331A (ja)	2006-03-10	2009-08-20	マクロジェニクス，インコーポレーテッド	変異型重鎖を有する抗体の同定および工学的改変ならびにその使用方法
KR100847010B1 (ko) *	2006-07-05	2008-07-17	아주대학교산학협력단	세포사멸 수용체 5 (ｄｒ5)에 특이적으로 결합하는 항체 및이를 포함하는 암 예방 또는 치료용 조성물
WO2009002947A2 (fr)	2007-06-22	2008-12-31	Affymax, Inc.	Composés et peptides de liaison au récepteur de trail
UA117901C2 (uk) *	2011-07-06	2018-10-25	Ґенмаб Б.В.	Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування

2012
- 2012-07-09 EP EP12305821.6A patent/EP2684896A1/fr not_active Withdrawn
2013
- 2013-07-09 PT PT13734785T patent/PT2877491T/pt unknown
- 2013-07-09 SI SI201331443T patent/SI2877491T1/sl unknown
- 2013-07-09 SG SG11201500177PA patent/SG11201500177PA/en unknown
- 2013-07-09 JP JP2015520954A patent/JP6457386B2/ja active Active
- 2013-07-09 ES ES13734785T patent/ES2727486T3/es active Active
- 2013-07-09 IN IN143DEN2015 patent/IN2015DN00143A/en unknown
- 2013-07-09 US US14/413,194 patent/US9611327B2/en active Active
- 2013-07-09 CA CA2878790A patent/CA2878790C/fr active Active
- 2013-07-09 WO PCT/EP2013/064466 patent/WO2014009358A1/fr not_active Ceased
- 2013-07-09 EP EP13734785.2A patent/EP2877491B1/fr active Active
- 2013-07-09 SG SG10201700148UA patent/SG10201700148UA/en unknown
- 2013-07-09 CN CN201380036952.2A patent/CN104619725B/zh active Active
- 2013-07-09 PL PL13734785T patent/PL2877491T3/pl unknown
- 2013-07-09 BR BR112015000449-0A patent/BR112015000449B1/pt active IP Right Grant
- 2013-07-09 DK DK13734785.2T patent/DK2877491T3/da active
- 2013-07-09 EP EP19159204.7A patent/EP3575323B1/fr active Active
2015
- 2015-01-11 IL IL23665115A patent/IL236651B/en active IP Right Grant
2017
- 2017-02-17 US US15/436,583 patent/US10647774B2/en active Active
2019
- 2019-09-22 IL IL269527A patent/IL269527B/en unknown
2020
- 2020-04-06 US US16/841,306 patent/US20200332016A1/en not_active Abandoned
2023
- 2023-09-06 US US18/461,910 patent/US20240141057A1/en active Pending

Also Published As

Publication number	Publication date
CN104619725A (zh)	2015-05-13
JP2015527992A (ja)	2015-09-24
HK1211044A1 (en)	2016-05-13
CA2878790A1 (fr)	2014-01-16
EP2877491B1 (fr)	2019-02-27
IL236651B (en)	2019-10-31
SG10201700148UA (en)	2017-02-27
US20170260281A1 (en)	2017-09-14
SI2877491T1 (sl)	2019-08-30
ES2727486T3 (es)	2019-10-16
BR112015000449B1 (pt)	2022-12-20
US20240141057A1 (en)	2024-05-02
SG11201500177PA (en)	2015-03-30
BR112015000449A2 (fr)	2017-08-15
IL269527A (en)	2019-11-28
US20150139997A1 (en)	2015-05-21
PT2877491T (pt)	2019-06-07
CA2878790C (fr)	2023-09-26
JP6457386B2 (ja)	2019-01-23
EP2684896A1 (fr)	2014-01-15
EP3575323A1 (fr)	2019-12-04
WO2014009358A1 (fr)	2014-01-16
EP3575323B1 (fr)	2024-09-11
CN104619725B (zh)	2019-04-23
PL2877491T3 (pl)	2020-01-31
US10647774B2 (en)	2020-05-12
US9611327B2 (en)	2017-04-04
IL236651A0 (en)	2015-02-26
EP2877491A1 (fr)	2015-06-03
US20200332016A1 (en)	2020-10-22
IL269527B (en)	2021-12-01
DK2877491T3 (da)	2019-06-03

Publication	Publication Date	Title
IN2015DN00143A (fr)	2015-06-12
IL242273B (en)	2018-10-31	Methods and compositions for increasing regulatory t cells + 4cd
GB2515195B (en)	2015-12-16	Improved fuel cell systems and methods
EP3480321B8 (fr)	2021-03-10	Analyse de cellule unique massivement parallèle
IL244511A0 (en)	2016-04-21	Cell culture in a metabolically optimal manner
EP3082840A4 (fr)	2017-11-22	Méthodes et dosages biologiques se rapportant à des cellules tumorales circulantes
EP2970881A4 (fr)	2017-01-25	Compositions et procédés de reprogrammation de lignées de cellules souches hématopoïétiques
IL240881A0 (en)	2015-10-29	Expression of the t cell balance gene, preparations, materials and methods for its use
EP3114716A4 (fr)	2017-07-26	Cellules de batterie et agencements
EP3028328A4 (fr)	2017-01-04	Cellule électro-synthétique ou électro-énergétique avec électrode(s) à diffusion de gaz
EP3083658A4 (fr)	2017-07-12	Méthodes et analyses associées à des cellules tumorales circulantes
EP3080855A4 (fr)	2017-07-26	Cellules électrochimiques et composants associés
EP3013424A4 (fr)	2017-03-29	Procédés et compositions de modulation des cellules souches cancéreuses
EP3147974A4 (fr)	2017-08-02	Ensemble batterie et bloc de piles
EP3072953A4 (fr)	2017-08-02	Récipient de culture de cellules et récipient dans lequel une culture de cellule a été logée
GB201319966D0 (en)	2013-12-25	Fuel cell assembly and method
EP3046171A4 (fr)	2017-05-17	Pile à combustible et empilage de pile à combustible
GB201418271D0 (en)	2014-11-26	Fuel cell and battery
EP3052104A4 (fr)	2017-06-14	Traitement de l'inflammation en utilisant des conjugués de llp2a-bisphosphonate et des cellules souches mésenchymateuses
EP2919309A4 (fr)	2015-12-30	Élément de scellement pour pile à combustible et corps de scellement pour pile à combustible l'utilisant
GB201306326D0 (en)	2013-05-22	Fuel cells
ZA201505170B (en)	2025-02-26	Tablets with improved acceptance and good storage stability
EP3164127A4 (fr)	2017-11-22	Compositions et méthodes d'amélioration de thérapies cellulaires adoptives
KR101882068B1 (ko)	2018-07-25	연료 전지의 작동
EP2970883B8 (fr)	2021-06-23	Cellules souches placentaires améliorées et leurs utilisations